Score Overview
Explore the 2021 public Archive ranking →
Where Neurocrine Biosciences Inc has ranked, year by year
Showing 1 year ranking history by HDB Score.
Top 50 on HDB Score for 1 year, since 2021, through 2021.
- NBIX
2001: 96.9% · 2021: 0.8% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-29 | $ 138.35 | — |
1 Year2025-09-29 | $ 140.27 | -1.37% |
5 Years2021-09-29 | $ 94.39 | 46.57% |
10 Years2016-09-29 | $ 50.33 | 174.89% |
20 Years2006-09-29 | $ 10.75 | 12x |
30 Years1996-09-27 | $ 11.00 | 12x |
All Time1996-05-23 | $ 12.50 | 11x |
| Period | Last Price2026-09-29 | 1 Year2025-09-29 | 5 Years2021-09-29 | 10 Years2016-09-29 | 20 Years2006-09-29 | 30 Years1996-09-27 | All Time1996-05-23 |
|---|---|---|---|---|---|---|---|
| Price | $ 138.35 | $ 140.27 | $ 94.39 | $ 50.33 | $ 10.75 | $ 11.00 | $ 12.50 |
| Return | — | -1.37% | 46.57% | 174.89% | 12x | 12x | 11x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 3.37B | $ 705M | $ 389M |
| 2025 | $ 2.86B | $ 478M | $ 1.48B |
| 2024 | $ 2.35B | $ 341M | $ 1.07B |
| 2023 | $ 1.88B | $ 249M | $ 1.03B |
| 2022 | $ 1.48B | $ 154M | $ 989M |
| 2021 | $ 1.13B | $ 89M | $ 711M |
| 2020 | $ 1.04B | $ 407M | $ 801M |
| 2019 | $ 788M | $ 37M | $ 670M |
| 2018 | $ 451M | $ 21M | $ 650M |
| 2017 | $ 161M | -$ 142M | $ 515M |
| 2016 | $ 15M | -$ 141M | $ 307M |
| 2015 | $ 19M | -$ 88M | $ 379M |
| 2014 | $ 0.00 | -$ 60M | $ 193M |
| 2013 | $ 2M | -$ 46M | $ 145M |
| 2012 | $ 53M | $ 5M | $ 173M |
| 2011 | $ 77M | $ 37M | $ 129M |
| 2010 | $ 33M | -$ 7M | $ 126M |
| 2009 | $ 2M | -$ 51M | $ 53M |
| 2008 | $ 3M | -$ 88M | $ 80M |
| 2007 | $ 1M | -$ 207M | $ 179M |
| 2006 | $ 39M | -$ 107M | $ 182M |
| 2005 | $ 123M | -$ 22M | $ 273M |
| 2004 | $ 85M | -$ 45M | $ 301M |
| 2003 | $ 139M | -$ 30M | $ 453M |
| 2002 | $ 18M | -$ 94M | $ 244M |
| 2001 | $ 41M | -$ 36M | $ 319M |
| 2000 | $ 14M | -$ 28M | $ 164M |
| 1999 | $ 16M | -$ 16M | $ 91M |
| 1998 | $ 16M | -$ 20M | $ 11M |
| 1997 | $ 26M | $ 5M | $ 15M |
| IPO1996 | $ 19M | $ 5M | $ 11M |
Neurocrine Biosciences Inc fundamental performance
Between 2020 and 2025, revenue grew from $ 1.04B to $ 2.86B and net income grew from $ 407M to $ 478M. Revenue increased in every one of those 5 years; net income in every one.
Between 2015 and 2025, revenue grew from $ 19M to $ 2.86B and net income went from -$ 88M to $ 478M. Revenue increased in every one of those 10 years; net income in 8.
Neurocrine Biosciences Inc currently holds a 20-year HDB Score of 6.4 out of 10. How the HDB Score is calculated.
Membership
Continue NBIX’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,814 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
